- Novartis (NVS -0.7%) says it has launched a safety review of its Beovu macular degeneration drug after the American Society of Retina Specialists raised concerns.
- More news on: Novartis AG, Healthcare stocks news, Read more ...
Market Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
Novartis AG Company Name:
NVS Stock Symbol:
Market:
Tuesday, Novartis AG (NYSE:NVS) received FDA approval for its Lutathera (lutetium Lu 177 dotatate / INN: lu...
2024-04-23 18:25:09 ET Scooting past analyst estimates for its latest quarter gave Novartis (NYSE: NVS) a lift on Tuesday. Investors like what they heard about the global healthcare company's inaugural earnings release for 2024, and rewarded Novartis with a more than 2% lift in its ...
2024-04-23 15:00:03 ET Wan Nurhayati from CFRA issued a price target of $108.00 for NVS on 2024-04-23 13:11:00. The adjusted price target was set to $108.00. At the time of the announcement, NVS was trading at $97.27. NVS currently trades -10.58% versus its 52 week high ...